Ascletis Pharma announced new data presentations at the 33rd European Congress on Obesity, highlighting their obesity drug candidates. ASC47 combined with semaglutide showed up to 111.8% greater weight loss compared to semaglutide alone. ASC36 demonstrated a much longer half-life and superior weight loss effects in preclinical models compared to existing treatments. These advancements suggest potential new effective therapies for obesity management, with further clinical development anticipated.
East West Bancorp is set to report strong Q2 2026 earnings with an expected EPS of $2.61 and revenue of $785.94 million, reflecting an 11.8% revenue increase and 14.5% EPS growth year-over-year. The bank shows robust financial health with expanding d...
AerCap has selected GE Aerospace's GEnx-1B engines to power 15 additional Boeing 787 Dreamliners, reinforcing its position as the largest owner of these aircraft. The GEnx engine is known for its high reliability and long service life, with a 99.98% ...
Crédit Agricole Brie Picardie conducted share buybacks totaling 13,057 shares from July 13 to July 17, 2026, with daily volumes ranging from 1,605 to 5,095 shares. These transactions were carried out under Article 5 of the Market Abuse Regulation (MA...
Northland Securities has increased its price target for Ouster to $60, reflecting a 55.88% upside from the current price. Ouster, a company specializing in digital LiDAR sensors for autonomous vehicles and robotics, aims to reach EBITDA breakeven wit...
Bank of America recently launched its BofA Rewards™ Program, enrolling over 3 million clients in just seven weeks, signaling strong customer interest. Meanwhile, Representative James A. Himes sold Bank of America shares valued between $1,001 and $15,...
